Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.


Journal Article

PURPOSE: Although much is known about the safety of an anticancer agent at the time of initial marketing approval, sponsors customarily collect comprehensive safety data for studies that support supplemental indications. This adds significant cost and complexity to the study but may not provide useful new information. The main purpose of this analysis was to assess the amount of safety and concomitant medication data collected to determine a more optimal approach in the collection of these data when used in support of supplemental applications. METHODS: Following a prospectively developed statistical analysis plan, we reanalyzed safety data from eight previously completed prospective randomized trials. RESULTS: A total of 107,884 adverse events and 136,608 concomitant medication records were reviewed for the analysis. Of these, four grade 1 to 2 and nine grade 3 and higher events were identified as drug effects that were not included in the previously established safety profiles and could potentially have been missed using subsampling. These events were frequently detected in subsamples of 400 patients or larger. Furthermore, none of the concomitant medication records contributed to labeling changes for the supplemental indications. CONCLUSION: Our study found that applying the optimized methodologic approach, described herein, has a high probability of detecting new drug safety signals. Focusing data collection on signals that cause physicians to modify or discontinue treatment ensures that safety issues of the highest concern for patients and regulators are captured and has significant potential to relieve strain on the clinical trials system.

Full Text

Duke Authors

Cited Authors

  • Kaiser, LD; Melemed, AS; Preston, AJ; Chaudri Ross, HA; Niedzwiecki, D; Fyfe, GA; Gough, JM; Bushnell, WD; Stephens, CL; Mace, MK; Abrams, JS; Schilsky, RL

Published Date

  • December 1, 2010

Published In

Volume / Issue

  • 28 / 34

Start / End Page

  • 5046 - 5053

PubMed ID

  • 20921453

Pubmed Central ID

  • 20921453

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.29.6608


  • eng

Conference Location

  • United States